CTCBIO Inc. announced that it expects to receive KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Kiwoom Securities Co., Ltd., Samsung Securities Co.,Ltd., KB Securities Co.,Ltd, Mirae Asset Daewoo Co., Ltd., Shinhan Investment Corp. other investors
October 01, 2018
Share
CTCBIO Inc. (KOSDAQ:A060590) announced a private placement of series 2 unregistered unguaranteed private convertible bonds for gross proceeds of KRW 21,000,000,000 on October 2, 2018. The transaction will involve participation from NH Investment & Securities Co., Ltd. for KRW 3,000,000,000; Kiwoom Securities Co., Ltd. for KRW 4,000,000,000; KB Securities Co., Ltd. on behalf of NH Absolute Return Hedge Fund 1st unit for KRW 2,000,000,000; Mirae Asset Daewoo Co., Ltd. on behalf of GVA Fortress-A Hedge Fund, GVA Saber-G Hedge Fund and GVA KOSDAQ Venture Hedge Fund for KRW 2,900,000,000; Yen H Investments Securities Corporation on behalf of GVA KOSDAQ IPO-I Hedge Fund for KRW 500,000,000; Shinhan Investment Corp. on behalf of Timefolio The Time-M2 Hedge Fund, Timefolio The Time-A2 Hedge Fund, Timefolio The Time-T2 Hedge Fund, Timefolio The Venture-V Hedge Fund, Timefolio KOSDAQ Venture Quant-I Hedge Fund for KRW 3,300,000,000; and Samsung Securities Co.,Ltd. on behalf of NH Absolute Pre IPO Mezzanine Hedge Fund 1, GVA Fortress-V Hedge Fund, GVA Saber-E Hedge Fund, GVA Mezz-V Hedge Fund, Timefolio The Time-A Hedge Fund, Timefolio The Venture-G Hedge Fund and Timefolio KOSDAQ Venture Hedge-S Fund for KRW 5,300,000,000.
The bonds will have no coupon rate and yield to maturity of 2% each maturing on October 4, 2023. The bonds will be fully convertible into 1,621,621 shares of the company at a fixed conversion price of KRW 12,950 per share from October 4, 2019 to September 4, 2023. The subscription and payment date of the transaction is October 4, 2018.
The transaction was approved by the board of directors of the company.
CTCBIO Inc. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals, veterinary drugs, animal feed supplements and functional foods. It pharmaceuticals include anticancer agents, antibiotics, bone injury treatments, antiulcer agents, blood flow stimulants and others. Its veterinary drugs include vaccines, antibiotics, immune enhancers, enzymes, organic acid, avian influenza-related agents and others. Its animal feed supplements include pigments, kapok seed meal, sesame meal and others. Its functional food business includes the development and manufacture of enzymes, lactobacillus and related products mainly used in dairy products. It also involves in the development of pharmaceutical manufacturing technology and know-how. The Company distributes its products within domestic market and to overseas markets.
CTCBIO Inc. announced that it expects to receive KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Kiwoom Securities Co., Ltd., Samsung Securities Co.,Ltd., KB Securities Co.,Ltd, Mirae Asset Daewoo Co., Ltd., Shinhan Investment Corp. other investors